NASDAQ:BMRN
$88.49
(
-0.276%
)
Friday, 26th May 2023
BioMarin Pharmaceutical Inc. Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $87.81 | $97.42 | Friday, 26th May 2023 BMRN stock ended at $88.49. This is 0.276% less than the trading day before Thursday, 25th May 2023. During the day the stock fluctuated 1.50% from a day low at $88.48 to a day high of $89.81. |
| 90 days | $87.34 | $103.58 | |
| 52 weeks | $70.73 | $117.77 |
Historical BioMarin Pharmaceutical Inc. prices
| Date | Open | High | Low | Close | Volume |
| 2023-05-26 | $88.89 | $89.81 | $88.48 | $88.49 | 711 493 |
| 2023-05-25 | $89.95 | $89.95 | $87.81 | $88.73 | 941 504 |
| 2023-05-24 | $91.76 | $91.80 | $90.38 | $90.54 | 658 324 |
| 2023-05-23 | $92.43 | $93.27 | $91.64 | $91.99 | 732 694 |
| 2023-05-22 | $92.04 | $93.11 | $91.80 | $92.77 | 591 091 |
| 2023-05-19 | $92.53 | $93.35 | $91.53 | $91.90 | 766 254 |
| 2023-05-18 | $92.48 | $92.48 | $91.16 | $92.23 | 622 183 |
| 2023-05-17 | $92.52 | $92.75 | $91.41 | $92.27 | 825 166 |
| 2023-05-16 | $93.61 | $94.41 | $90.99 | $92.02 | 1 204 524 |
| 2023-05-15 | $94.04 | $96.47 | $93.93 | $95.18 | 973 401 |
| 2023-05-12 | $96.05 | $96.16 | $93.37 | $93.93 | 1 054 201 |
| 2023-05-11 | $95.15 | $95.40 | $93.94 | $95.39 | 806 393 |
| 2023-05-10 | $96.02 | $96.02 | $93.94 | $95.14 | 773 250 |
| 2023-05-09 | $95.49 | $95.98 | $93.80 | $95.61 | 835 998 |
| 2023-05-08 | $96.69 | $96.74 | $95.08 | $95.94 | 771 256 |
| 2023-05-05 | $95.79 | $97.13 | $94.84 | $96.63 | 913 075 |
| 2023-05-04 | $93.89 | $95.47 | $92.30 | $95.45 | 791 491 |
| 2023-05-03 | $93.64 | $94.50 | $93.04 | $93.58 | 960 951 |
| 2023-05-02 | $96.29 | $96.77 | $93.62 | $93.82 | 1 039 942 |
| 2023-05-01 | $96.54 | $97.42 | $95.30 | $96.98 | 1 027 387 |
| 2023-04-28 | $92.07 | $96.55 | $91.96 | $96.04 | 1 703 077 |
| 2023-04-27 | $92.07 | $93.40 | $89.25 | $92.45 | 1 941 038 |
| 2023-04-26 | $94.67 | $95.00 | $92.67 | $93.00 | 1 509 988 |
| 2023-04-25 | $96.35 | $96.76 | $94.90 | $95.57 | 993 500 |
| 2023-04-24 | $97.80 | $97.93 | $95.66 | $96.16 | 1 265 449 |
| 2023-04-21 | $97.05 | $98.06 | $96.57 | $97.51 | 1 723 878 |
| 2023-04-20 | $98.55 | $98.36 | $96.48 | $96.82 | 1 203 352 |
| 2023-04-19 | $98.40 | $99.51 | $98.13 | $99.06 | 962 938 |
| 2023-04-18 | $100.25 | $100.31 | $98.11 | $98.41 | 759 094 |
| 2023-04-17 | $99.55 | $100.38 | $98.83 | $100.30 | 881 152 |
| 2023-04-14 | $98.40 | $99.18 | $98.06 | $99.01 | 841 727 |
| 2023-04-13 | $97.31 | $98.98 | $97.31 | $98.34 | 1 039 282 |
| 2023-04-12 | $99.00 | $99.45 | $97.85 | $97.96 | 862 626 |
| 2023-04-11 | $98.06 | $98.82 | $97.48 | $97.84 | 1 026 892 |
| 2023-04-10 | $99.56 | $99.66 | $97.28 | $98.05 | 885 527 |
| 2023-04-06 | $96.28 | $99.80 | $95.75 | $99.60 | 1 486 600 |
| 2023-04-05 | $95.99 | $96.99 | $95.47 | $96.57 | 1 072 242 |
| 2023-04-04 | $96.80 | $96.86 | $95.13 | $95.43 | 946 542 |
| 2023-04-03 | $97.09 | $97.42 | $96.46 | $96.60 | 881 347 |
| 2023-03-31 | $95.57 | $97.70 | $95.56 | $97.24 | 1 434 386 |
| 2023-03-30 | $94.45 | $95.89 | $94.34 | $95.29 | 1 226 528 |
| 2023-03-29 | $91.89 | $94.45 | $91.39 | $94.20 | 1 072 586 |
| 2023-03-28 | $91.23 | $92.10 | $90.81 | $91.44 | 859 877 |
| 2023-03-27 | $91.50 | $92.10 | $91.10 | $91.50 | 1 078 191 |
| 2023-03-24 | $90.01 | $91.16 | $89.34 | $90.74 | 771 823 |
| 2023-03-23 | $91.69 | $91.69 | $89.35 | $90.11 | 1 244 800 |
| 2023-03-22 | $92.25 | $92.25 | $89.98 | $90.08 | 963 168 |
| 2023-03-21 | $92.24 | $92.82 | $91.77 | $92.08 | 1 581 097 |
| 2023-03-20 | $92.07 | $93.76 | $91.23 | $92.34 | 1 201 310 |
| 2023-03-17 | $92.37 | $92.45 | $90.49 | $91.67 | 1 757 429 |
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o... BMRN Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
